bosutinib

It is used in adults as well as in children and adolescents over 6 years of age with Ph-positive chronic myeloid leukemia. It may be used in cases of newly diagnosed disease or when previous treatment has not been effective. The medicine is also used in the accelerated phase and the blast crisis phase of this leukemia.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: MSN Labs Europe Limited Pharmadox Healthcare Limited

This medicine is used in adults as well as in children and adolescents over 6 years of age with Ph-positive chronic myeloid leukemia. It may be used in newly diagnosed disease or when previous treatment has not been effective. It is also used in patients in the accelerated phase or the blast crisis phase.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: MSN Labs Europe Limited Pharmadox Healthcare Limited

The medicine is used in adults and children and adolescents (over 6 years of age) suffering from Ph-positive chronic myeloid leukemia. It is intended for individuals in whom the disease has been newly diagnosed or in whom previous treatment has not been effective.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: MSN Labs Europe Limited Pharmadox Healthcare Limited

The medicine is intended for adult patients with chronic myeloid leukemia with the presence of the Philadelphia chromosome (Ph-positive type), who have newly diagnosed disease or for whom previous treatment has not been effective or appropriate.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Coripharma ehf.

The medicine is intended for adult patients with chronic myeloid leukemia with the presence of the Philadelphia chromosome (Ph-positive type). It is used in cases of newly diagnosed disease or when previous medications have not yielded the expected results.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Coripharma ehf.

The medicine is used in adults and children over 6 years of age for the treatment of chronic myeloid leukemia (Ph-positive type) in the newly diagnosed phase, the accelerated phase, or the blast crisis phase, when previous treatment has been ineffective or inappropriate.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Lek Pharmaceuticals d.d., Pharmadox Healthcare Limited, Salutas Pharma GmbH

The medicine is used in adults and children over 6 years of age for the treatment of chronic myeloid leukemia (Ph-positive type) in the newly diagnosed phase or in patients for whom previous treatment has not been effective. It is also used in adults in the accelerated phase and the blast crisis phase of this disease.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Lek Pharmaceuticals d.d., Pharmadox Healthcare Limited, Salutas Pharma GmbH

The medicine is used in adults and children over 6 years of age for the treatment of chronic myeloid leukemia (Ph-positive type), when the disease has been newly diagnosed or when previous treatments have not been effective. It is also used in adults in the accelerated phase or blast crisis of this disease.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Lek Pharmaceuticals d.d., Pharmadox Healthcare Limited, Salutas Pharma GmbH

This medicine is used in adult patients with Ph-positive chronic myeloid leukemia, who have newly diagnosed disease or for whom previous treatment has not been effective or has been inappropriate.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Clonmel Healthcare Ltd., Coripharma ehf., STADA Arzneimittel AG, Germany

The medicine is intended for adult patients with Ph-positive chronic myeloid leukemia who have newly diagnosed disease or for whom previous treatment has not been effective.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Clonmel Healthcare Ltd., Coripharma ehf., STADA Arzneimittel AG, Germany

The medicine is intended for adult patients with chronic myeloid leukemia with the presence of the Philadelphia chromosome (Ph-positive type), who have newly diagnosed disease or for whom previous treatment has not been effective or appropriate.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Clonmel Healthcare Ltd., Coripharma ehf., STADA Arzneimittel AG, Germany

This medicine is used in adult patients with Ph-positive chronic myeloid leukemia, who have newly diagnosed disease or for whom previous treatment has not been effective or has been inappropriate.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Coripharma ehf.

The medicine is intended for adult patients with Ph-positive chronic myeloid leukemia, who have newly diagnosed disease or for whom previous treatment has been ineffective or inappropriate.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Coripharma ehf.

The medicine is intended for adult patients with Ph-positive chronic myeloid leukemia. It is used in individuals whose disease has only recently been diagnosed or in those for whom previous treatment has not been effective.

Form: tablets, film-coated

ATC: L01EA04

Manufacturer: Coripharma ehf.